SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst a fervent debate over Bitcoin's near-term price direction, with discussions highlighting recent ETF outflows and broader market dynamics. The community remains sharply divided, as many anticipate a "parabolic" rally for Bitcoin as a hedge against inflation, while others warn of an impending "crypto winter" and significant price corrections based on historical cycles and perceived lack of intrinsic value.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF ($ETHA) is trending amidst strong speculation surrounding spot Ethereum ETF approvals, particularly those offering staking, which is expected to drive institutional demand. The recent "Fusaka Upgrade" is also a key talking point, with its impact on Ethereum's burn rate fueling bullish outlooks and active options trading. While many investors are actively 'buying the dip' and positioning for a potential decoupling from Bitcoin, others maintain caution regarding crypto market volatility.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is generating significant buzz after the FDA accepted its Biologics License Application for Veligrotug, granting Priority Review for Thyroid Eye Disease and setting a PDUFA target. The community is widely discussing Veligrotug's potential as a best-in-class treatment, citing its strong efficacy across both active and chronic TED compared to current therapies, which fuels analyst upgrades and M&A speculation for the company's innovative pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is the Options Market Predicting a Spike in Ultrapar Participacoes Stock?

Investors need to pay close attention to Ultrapar Participacoes stock based on the movements in the options market lately.

Ultrapar Participacoes S.A. (NYSE:UGP) Given Average Recommendation of "Buy" by Brokerages

Shares of Ultrapar Participacoes S.A. (NYSE:UGP - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports...

Ultrapar Participacoes S.A. (NYSE:UGP) Given Consensus Rating of "Buy" by Brokerages

Shares of Ultrapar Participacoes S.A. (NYSE:UGP - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven ratings firms that are currently covering the stock...

Ultrapar Participacoes (NYSE:UGP) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Ultrapar Participacoes (NYSE:UGP) Stock Price Passes Above 200-Day Moving Average - Time to Sell...

Ultrapar Participacoes (NYSE:UGP) Stock Price Down 6.4% - Should You Sell?

Ultrapar Participacoes (NYSE:UGP) Shares Down 6.4% - Here's Why...

Ultrapar Participacoes (NYSE:UGP) Shares Gap Up - Time to Buy?

Ultrapar Participacoes (NYSE:UGP) Shares Gap Up - Here's What Happened...

Ultrapar Participacoes (NYSE:UGP) Sets New 52-Week High - Time to Buy?

Ultrapar Participacoes (NYSE:UGP) Reaches New 52-Week High - Still a Buy...

Ultrapar Participacoes S.A. Plans Special Dividend of $0.19 (NYSE:UGP)

Ultrapar Participacoes S.A. (NYSE:UGP) declared a special dividend on Wednesday, December 3rd. Investors of record on Friday, December 12th will be paid a dividend of 0.1876 per share by the oil and...

Ultrapar Participacoes S.A. (NYSE:UGP) Given Average Rating of "Buy" by Brokerages

Shares of Ultrapar Participacoes S.A. (NYSE:UGP - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One...

Raiffeisen Bank International AG Buys 144,685 Shares of Ultrapar Participacoes S.A. $UGP

Raiffeisen Bank International AG lifted its position in Ultrapar Participacoes S.A. (NYSE:UGP - Free Report) by 54.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The...

Ultrapar Participaçoes SA engages in the distribution and retail services including, fuel, liquefied petroleum gas (LPG), retail pharmacy, specialty chemicals and liquid bulk storage businesses. It operates through the following segments: Ultragaz, Ipiranga, Oxiteno, Ultracargo, Extrafarma and Others. The Ultragaz segment distributes LPG to residential, commercial and industrial consumers. The Ipiranga segment operates the distribution and marketing of gasoline, ethanol, diesel, fuel oil, kerosene, natural gas for vehicles, and lubricants and related activities. The Oxiteno segment produces ethylene oxide and its main derivatives and fatty alcohols. The Extrafarma segment trades pharmaceutical, hygiene and beauty products. The Other segment includes the parent company and subsidiaries Serma-Associacao dos Usuarios de Equipamentos de Processamento de Dados e Serviços Correlatos and Imaven Imoveis Ltda. The company was founded in 1937 and is headquartered in Sao Paulo, Brazil.

UGP
Ultrapar Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UGP News

UGPUltrapar Holdings Inc.